Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sunbless OC is a topical broad-spectrum sunscreen gel developed and marketed by La Pristine Bioceuticals. Specifically formulated for individuals with oily or acne-prone skin, the "OC" in its name denotes "Oil Control," highlighting its non-comedogenic and sebum-regulating properties. The product typically utilizes a combination of chemical UV filters, such as octinoxate (octyl methoxycinnamate), avobenzone, and oxybenzone, alongside physical blockers like zinc oxide to provide comprehensive protection against both ultraviolet A (UVA) and ultraviolet B (UVB) radiation. By absorbing, reflecting, and scattering solar radiation, Sunbless OC helps prevent sunburn, premature skin aging (photoaging), and reduces the long-term risk of skin cancer. It is a commercial dermatological product and does not have associated clinical trial phases in a traditional drug development pipeline.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Sunbless OC.